Journal article
Guidelines for vismodegib in the management of periocular basal cell carcinoma
Abstract
OBJECTIVE: The management of advanced basal cell carcinoma (BCC) in the periocular region remains a clinical challenge. Vismodegib (ErivedgeTM) has been approved in 2013 by Health Canada for adult patients with "histologically confirmed metastatic BCC or locally advanced BCC inappropriate for surgery or radiation." An expert consensus was sought to create a standardised approach in the use of this novel treatment.
METHODS: Fourteen practicing …
Authors
Hussain A; Tucker N; DeAngelis DD; Yin VT; Ing E; Arthurs B; Gill HS; Hardy I; Hurwitz J; Kratky V
Journal
Canadian Journal of Ophthalmology, Vol. 55, No. 3, pp. 245–252
Publisher
Elsevier
Publication Date
June 2020
DOI
10.1016/j.jcjo.2019.11.004
ISSN
0008-4182